|
| Histone code human growth and cancer |
|
https://doi.org/10.18632/oncotarget.435
Francesco Crea
|
| 1-2 |
|
| Histone modification defects in developmental disorders and cancer |
|
https://doi.org/10.18632/oncotarget.436
Nicholas CP Cross
|
| 3-4 |
|
| Epigenetic control of an oncogenic microRNA miR155 by BRCA1 |
|
https://doi.org/10.18632/oncotarget.433
Suhwan Chang, and Shyam K. Sharan
|
| 5-6 |
|
| The Safety of Embryonic Stem Cell Therapy Relies on Teratoma Removal |
|
https://doi.org/10.18632/oncotarget.434
Chad Tang, Irving L. Weissman, and Micha Drukker
|
| 7-8 |
|
| microRNA1/133a and microRNA206/133b clusters: Dysregulation and functional roles in human cancers |
|
https://doi.org/10.18632/oncotarget.424
Nijiro Nohata, Toyoyuki Hanazawa, Hideki Enokida, and Naohiko Seki
|
| 9-21 |
|
| Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells |
|
https://doi.org/10.18632/oncotarget.437
Max Schlaak, Patrick Schmidt, Christopher Bangard, Peter Kurschat, Cornelia Mauch, and Hinrich Abken
|
| 22-30 |
|
| A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIMdependent apoptosis in head and neck cancer |
|
https://doi.org/10.18632/oncotarget.430
Roland H. Stauber, Shirley K. Knauer, Negusse Habtemichael, Carolin Bier, Britta Unruhe, Simona Weisheit, Stephanie Spange, Frank Nonnenmacher, Verena Fetz, Torsten Ginter, Sigrid Reichardt, Claus Liebmann, Günter Schneider, and Oliver H. Krämer
|
| 31-43 |
|
| Tumor suppressive microRNA1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma |
|
https://doi.org/10.18632/oncotarget.417
Hideo Hidaka, Naohiko Seki, Hirofumi Yoshino, Takeshi Yamasaki, Yasutoshi Yamada, Nijiro Nohata, Miki Fuse, Masayuki Nakagawa, and Hideki Enokida
|
| 44-57 |
|
| “Picolog†a SyntheticallyAvailable Bryostatin Analog Inhibits Growth of MYCInduced Lymphoma In Vivo |
|
https://doi.org/10.18632/oncotarget.438
Brian A. DeChristopher, Alice C. Fan, Dean W. Felsher, and Paul A. Wender
|
| 58-66 |
|
| Capturing the Molecular and Biological Diversity of HighGrade Astrocytoma in Genetically Engineered Mouse Models |
|
https://doi.org/10.18632/oncotarget.425
Lionel M.L. Chow, and Suzanne J. Baker
|
| 67-77 |
|
| Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer |
|
https://doi.org/10.18632/oncotarget.332
Helen M. Coley, Eleftheria Hatzmichael, Sarah P. Blagden, Iain A. McNeish, Alastair Thompson, Tim Crook, and Nelofer Syed
|
| 78-83 |
|
| Recent Developments in Targeting Carbonic Anhydrase IX for Cancer Therapeutics |
|
https://doi.org/10.18632/oncotarget.422
Paul C. McDonald, Jean-Yves Winum, Claudiu T. Supuran, and Shoukat Dedhar
|
| 84-97 |
|
| Neoplastic cells are a rare component in human glioblastoma microvasculature |
|
https://doi.org/10.18632/oncotarget.427
Fausto J. Rodriguez, Brent A. Orr, Keith L. Ligon, and Charles G. Eberhart
|
| 98-106 |
|
| Curtailing side effects in chemotherapy: a tale of PKCδ in cisplatin treatment |
|
https://doi.org/10.18632/oncotarget.439
Navjotsingh Pabla, and Zheng Dong
|
| 107-111 |
